Description du projet
Nouvel outil de diagnostic rénal pour prévenir l’insuffisance rénale aiguë
Selon les statistiques, chaque année, environ 1,7 million de personnes dans le monde meurent d’une insuffisance rénale aiguë (IRA) qui, dans de nombreux cas, se développe pendant un traitement en unité de soins intensifs. Le meilleur traitement de cette complication est la prévention en temps utile. Le projet Clarity, financé par l’UE, introduit un système de surveillance des soins intensifs qui utilise une technologie de capteurs brevetée, permettant d’analyser la composition et le volume de flux urinaire en constante évolution, et d’informer le personnel médical en temps réel des changements de ces paramètres sur une base continue. Cette information reflète les changements de la fonction rénale et fournit un signe précoce du risque d’IRA dans le but de faciliter une intervention immédiate. Le système a été testé lors des premiers essais cliniques et est actuellement en cours de préparation pour des essais cliniques à grande échelle.
Objectif
Intensive Care Unit (ICU)-acquired Acute Kidney Injury (AKI) is a prevalent and serious problem, associated with significantly increased morbidity and mortality. According to the Global Burden of Disease (GBD), each year around 1.7 million people worldwide are estimated to die from AKI. AKI develops in over 57% of ICU patients, requiring an average of 3.5 additional hospital days and €13,000 of additional hospital costs per patient. The best treatment for AKI is prevention. Although there is no curative therapy for AKI, research over the past decade identified various means to prevent or limit AKI. Unfortunately, these are not widely known and are variably practiced worldwide resulting in lost opportunities to improve the care and outcomes of patients with AKI.
RenalSense introduces Clarity RMS™, a critical care monitoring system that continuously measures urine flow, automatically transmitting to the medical staff real-time data and alerts of fluctuations, on a 24/7 basis. Using patented sensor technology, Clarity measures, analyses and interprets the continuously changing composition and flow volume of urine. This information, which reflects changes in renal function, provides an early sign of AKI risk and facilitates rapid intervention. In addition, it is invaluable for monitoring treatment efficacy and managing fluid balance. The system has been tested during clinical trials with Herzog hospital, Hadassah Medical Organisation and University of Pittsburgh. Analysis of 1,000 study hours showed that electronic measurements with Clarity were more consistent, reliable and accurate than nursing records.
During the feasibility assessment, RenalSense will establish a go-to-market strategy, as well as a feasible product development plan and industrialization strategy. The plan for the large-scale clinical trials will be defined, and the participants secured.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
91450 JERUSALEM
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.